| answer text |
<p>We have no plans to do so. Decisions on which drugs are made available through
the Cancer Drugs Fund are for NHS England’s Cancer Drugs Fund panel, in accordance
with the Standard Operating Procedures for the Fund.</p><p> </p><p> </p><p> </p><p>There
are two drugs for the second-line treatment of renal cell carcinoma – Afinitor (everolimus)
and Inlyta (axitinib) - currently available through the Fund.</p><p> </p><p> </p><p>
</p><p>Inlyta is also being appraised for this condition by the National Institute
for Health and Care Excellence and final draft guidance recommending its use was published
on 16 December 2014.</p><p> </p><p> </p><p> </p><p>NHS England has assured the Department
that no patient whose treatment is currently being funded through the Cancer Drugs
Fund will have funding withdrawn, as long as it is clinically appropriate that they
continue to receive that treatment. In addition, no drug will be removed from the
Fund where it is the only therapy for that condition.</p><p> </p><p><strong> </strong></p><p>
</p><p><strong> </strong></p><p> </p>
|
|
